Are UTZ, VCTR, FULC, CZR Obtaining Fair Deals for their Shareholders?
Are UTZ, VCTR, FULC, CZR Obtaining Fair Deals for their Shareholders? Are UTZ, VCTR, FULC, CZR Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 28, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...
PR Newswire
Are WEAV, FULC, BRBS Obtaining Fair Deals for their Shareholders?
Are WEAV, FULC, BRBS Obtaining Fair Deals for their Shareholders? Are WEAV, FULC, BRBS Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 24, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...
PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC $HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC PR Newswire NEW YORK, Aug. 23, 2026 NEW YORK, Aug. 23, 2026 /PRNewswire...
PR Newswire
Are MITT, ARX, HHS, FULC Obtaining Fair Deals for their Shareholders?
Are MITT, ARX, HHS, FULC Obtaining Fair Deals for their Shareholders? Are MITT, ARX, HHS, FULC Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 17, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...
PR Newswire
Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders
Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders PR Newswire MILWAUKEE, Aug. 17, 2026...
PR Newswire
Fulcrum Therapeutics Strikes All-Stock Merger With Slate Medicines
Fulcrum Therapeutics and Slate Medicines merge in an all-stock deal to develop migraine drugs, backed by a $245M private placement.read more...
Benzinga
Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies
Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies...
Yahoo! Finance: News
FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) and Slate Medicines, Inc. Upon closing of the proposed transaction, Fulcrum shareholders are expected to own 5.0% of the combined company. Halper Sadeh encourages Fulcrum...
Business Wire
Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Fulcrum Therapeutics (FULC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks
FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud
Shareholders of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) saw the stock plunged roughly 50% on June 1, 2026, following disclosure of an FDA safety concerns related to the PRC2 inhibitor drug class. Those who lost money on FULC are encouraged tosubmit their information immediately. You may also...
Business Wire